ClinicalTrials.gg
CompletedNCT05137600Updated Feb 4, 2022

A Drug-Drug Interaction Study Between ATI-2173 and Midazolam or Clarithromycin in Healthy Subjects

A Phase 1 interventional study of ATI-2173 and Midazolam in Drug Drug Interaction, sponsored by Antios Therapeutics, Inc. Completed at 1 site in Canada. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-02-04.

Sponsored by Antios Therapeutics, Inc · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This study is a single-center, open-label, 2-cohort, fixed-sequence, DDI study in healthy adult subjects. Healthy volunteers will be administered multiple oral doses of ATI-2173 in combination with midazolam or clarithromycin and assessed for safety and tolerability including blood tests to show how the body metabolizes and eliminates the investigational drug as well as how the investigational drug interacts with midazolam or clarithromycin.

02

Conditions studied

  • Drug Drug Interaction
03

In context

Lead sponsor

Antios Therapeutics, Inc is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated Form (ICF)
  2. Stated willingness to comply with all study procedures (including ability and willingness to abstain from alcohol from 48 hours prior to the first study drug administration until discharge) and availability for the duration of the study
  3. Healthy adult male or female
  4. Aged between 18 and 60 years, inclusive
  5. (BMI) within 18.5 kg/m2 to 30.0 kg/m2, inclusively
  6. Non- or ex-smoker (an ex-smoker is defined as someone who completely stopped using nicotine products for at least 180 days prior to the first study drug administration)
  7. Suitable veins for cannulation or repeated venipuncture as assessed by an Investigator at Screening
  8. If female, meets one of the following criteria:

    1. Is of and agrees to use an acceptable method. Acceptable contraceptive methods include

      • Abstinence from heterosexual intercourse from the first study drug administration through to at least 60 days after the last dose of the study drug
      • Non-hormonal intrauterine device (IUD) with a barrier method (eg, male condom) used from at least 28 days prior to the first study drug administration through to at least 60 days after the last dose of the study drug
      • Double-barrier method (eg, male condom, spermicide and diaphragm or cervical cap used simultaneously )from Screening through to at least 60 days after the last dose of the study drug
      • Male partner vasectomized at least 6 months prior to Screening Or
    2. Is of non-childbearing potential, defined as surgically sterile (ie, has undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation) or is in a state (ie, at least 1 year without menses without an alternative medical condition prior to the first study drug administration), as confirmed by follicle-stimulating hormone levels (≥ 40 mIU/mL).
  9. If male, meets one of the following criteria:

    1. Is able to procreate and agrees to use one of the accepted contraceptive regimens and not to donate sperm from the first study drug administration to at least 90 days after the last drug administration. An acceptable method of contraception includes one of the following:

      • Abstinence from heterosexual intercourse
      • Male condom with spermicide or male condom with a vaginal spermicide (gel, foam, or suppository) Or
    2. Is unable to procreate; defined as surgically sterile (ie, has undergone a vasectomy at least 6 months prior to Screening)
  10. Agrees to abstain from blood or plasma donation from the Screening visit until 3 months after the last study drug administration
  11. Have no diseases captured in the medical history or evidence of clinically significant findings on the physical examination, vital signs, myopathy questionnaire, and/or , as determined by an Investigator Cohort 1 only
  12. Have no clinically significant findings on the neurological examination and/or oxygen saturation measurement as determined by an Investigator

Exclusion criteria

Exclusion Criteria:

  1. Female who is lactating
  2. Female who is pregnant according to the pregnancy test at Screening or prior to the first study drug administration
  3. Female using the following systemic : oral, patch or vaginal ring, in the 28 days prior to the first study drug administration
  4. Female using hormone replacement therapy in the 28 days prior to the first study drug administration
  5. Female using the following systemic contraceptives: injections or implant, or hormone-releasing IUD in the 13 weeks prior to the first study drug administration
  6. Seated pulse rate less than 50 beats per minute or more than 100 beats per minute at Screening or prior to the first study drug administration
  7. Seated blood pressure below 105/60 mmHg or higher than 140/90 mmHg at Screening or prior to the first study drug administration
  8. Estimated (eGFR) ≤ 60 mL/min/1.73m2, calculated using the Modification of Diet in Renal Disease (MDRD) equation, at Screening or prior to the first study drug administration
  9. Presence of out-of-range cardiac interval (PR \< 110 msec, PR > 200 msec, QRS \< 60 msec, QRS >110 msec and > 440 msec) on the at Screening or at Check-in or other ECG abnormalities, unless deemed non-significant by an Investigator
  10. value below the lower limit of the reference laboratory at Screening or prior to study drug administration
  11. Any other clinically significant abnormalities in laboratory test results at Screening. Subjects with (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), creatine kinase (CK) or total outside the normal range at Screening or Day -1 will be excluded.
  12. Positive test result for alcohol and/or drugs of abuse at Screening or prior to the first drug administration
  13. Positive screening results to Ag/Ab combo, surface antigen or virus antibody tests at Screening
  14. Positive screening results to SARS-CoV-2 virus tests prior to the first study drug administration
  15. History of significant to ATI-2173, clevudine, midazolam, clarithromycin, or any related products (including of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs
  16. Presence or history of significant gastrointestinal, liver or kidney disease, or surgery that may affect drug bioavailability
  17. History of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic or dermatologic disease
  18. Presence of clinically significant muscle disorders, myopathies or other forms of liver disease
  19. Maintenance therapy with any drug or significant history of drug dependency or alcohol abuse (> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic)
  20. Any clinically significant illness in the 28 days prior to the first study drug administration
  21. Use of any prescription drugs (including hormonal contraceptives and hormone replacement therapy) or any inhibitors, inducers, or substrates in the 30 days prior to the first study drug administration, that in the opinion of an Investigator would put into question the status of the participant as healthy
  22. Use of St. John's wort in the 30 days prior to the first study drug administration
  23. Use of over-the-counter (OTC) medications, herbal supplements, and vitamins in the 14 days prior to the first study treatment administration.
  24. Use of quinine-containing products (eg, tonic water), grapefruit products, pomelo products, Seville orange products, including supplements containing Citrus aurantium or "bitter orange", in the 14 days prior to the first study drug administration
  25. Consumption of food or beverages containing xanthines (ie, tea, coffee, cola drinks, energy drinks or chocolate) in the 48 hours prior to the first study drug administration
  26. Any history of tuberculosis
  27. Immunization with a coronaviruse disease 2019 (COVID-19) vaccine in the 14 days prior to the first study drug administration
  28. Scheduled immunization with a COVID-19 vaccine (first or second dose) during the study that, in the opinion of an Investigator, could potentially interfere with subject participation, subject safety, study results, or any other reason
  29. Inclusion in a previous group for this clinical study
  30. Participation in another clinical study with a non-biologic product (IP) or new formulation of a marketed non-biologic drug in the 30 days prior to Screening
  31. Participation in another clinical study with any marketed or investigational biologic product within 90 days or 5 half-lives, whichever is longer, prior to Screening
  32. Donation of 50 mL or more of blood in the 28 days prior to the first study drug administration
  33. Donation of 500 mL or more of blood (Canadian Blood Services, Hema-Quebec, clinical studies, etc.) in the 56 days prior to the first study drug administration Cohort 1
  34. Oxygen saturation (SpO2) below 95% at Screening or prior to the first study drug administration
  35. Family history of sudden cardiac death or known prolonged QTc
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    ATI-2173 50 mg

    ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth

    Drug: ATI-2173

  • Experimental
    Midazolam

    Midazolam is a sensitive CYP3A index substrate

    Drug: Midazolam

  • Experimental
    Clarithromycin

    Clarithromycin is a sensitive P-gp index inhibitor to evaluate potential effect of P-gp inhibition on ATI-2173 and its metabolites

    Drug: Clarithromycin

Interventions

  • ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth

  • Midazolam is a sensitive CYP3A index substrate

  • Clarithromycin is a sensitive P-gp index inhibitor to evaluate potential effect of P-gp inhibition on ATI-2173 and its metabolites(clarithromycin)

06

What researchers measure

Primary outcomes

  1. Cmax of Midazolam

    Time frame: Through end of study, approximately 3 months

  2. AUC0-t of Midazolam

    Time frame: Through end of study, approximately 3 months

  3. AUC0-inf of Midazolam

    Time frame: Through end of study, approximately 3 months

  4. Cmax of ATI-2173

    Time frame: Through end of study, approximately 3 months

  5. AUCtau of ATI-2173

    Time frame: Through end of study, approximately 3 months

  6. AUC0-t of ATI-2173

    Time frame: Through end of study, approximately 3 months

  7. AUCo-inf of ATI-2173

    Time frame: Through end of study, approximately 3 months

Secondary outcomes

  1. Number of adverse events

    Time frame: Through end of study, approximately 3 months

Other outcomes

  1. Cmax of 1-hydroxymidazolam

    Time frame: Through end of study, approximately 3 months

  2. AUC0-t of 1-hydroxymidazolam

    Time frame: Through end of study, approximately 3 months

  3. AUC0-inf of 1-hydroxymidazolam

    Time frame: Through end of study, approximately 3 months

  4. Ratio of metabolite to parent (midazolam) for AUC0-t

    Time frame: Through end of study, approximately 3 months

  5. Ratio of metabolite to parent (ATI-2173) for AUC0-t

    Time frame: Through end of study, approximately 3 months

  6. Ratio of metabolite to parent (ATI-2173) for AUCtau

    Time frame: Through end of study, approximately 3 months

  7. Cmax of M1

    Time frame: Through end of study, approximately 3 months

  8. AUC0-t of M1

    Time frame: Through end of study, approximately 3 months

  9. AUC0-inf of M1

    Time frame: Through end of study, approximately 3 months

  10. Cmax of clevudine

    Time frame: Through end of study, approximately 3 months

  11. AUCtau of clevudine

    Time frame: Through end of study, approximately 3 months

07

Study locations

1 site
  • Altasciences
    Montréal, Quebec H3P 3P1, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Dec 2021, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2021
First posted
Nov 30, 2021
StartActual
Oct 28, 2021
Primary completionActual
Dec 23, 2021
CompletionActual
Jan 23, 2022
Last update
Feb 4, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05137600
Lead sponsor
Antios Therapeutics, Inc
Responsible party
Sponsor
First posted
Nov 30, 2021
Start date
Oct 28, 2021
Primary completion
Dec 23, 2021
Completion
Jan 23, 2022
Last update
Feb 4, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fosclevudine alafenamide · Midazolam · Clarithromycin

Start the discussion